Aim: To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, Antiviral, Lopinavir, Ritonavir, adverse events, 【초록키워드】 Efficacy, therapy, mechanical ventilation, outcome, observational study, outcomes, Randomized, Efficacy and safety, incidence, body temperature, hospitalized COVID-19 patient, meta-analyses, Lopinavir–ritonavir, Clinical use, control group, hospitalized COVID-19 patients, significant increase, material, SARS-CoV-2 test, benefit, lack, evaluate, demonstrated, 【제목키워드】 Treatment, Meta-analysis, combination therapy, Lopinavir–ritonavir, hospitalized COVID-19,